Exane BNP Paribas Downgrades GlaxoSmithKline (GSK) to Underperform
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Price: $39.41 -0.48%
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 16
Rating Summary:
8 Buy, 13 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 16
Join SI Premium – FREE
Exane BNP Paribas downgraded GlaxoSmithKline (NYSE: GSK) from Outperform to Underperform.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $47.11 yesterday.
For an analyst ratings summary and ratings history on GlaxoSmithKline click here. For more ratings news on GlaxoSmithKline click here.
Shares of GlaxoSmithKline closed at $47.11 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Applus Services SA (APPS:SM) to Neutral
- Goldman Sachs Downgrades Pacific Biosciences of California (PACB) to Neutral
- UBS Downgrades SSP Group Plc. (SSPG:LN) (SSPPF) to Neutral
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
